The Business Research Company published its Filgrastim Biosimilars Global Market Report 2020 which provides strategists, marketers and senior management with the critical information they need to assess the global Filgrastim Biosimilars market. The report provides in-depth analysis of the impact of COVID-19 on the market, along with revised market numbers due to the effects of the coronavirus.
The report covers the Filgrastim Biosimilars market’s segments-
1) By Application: Oncology, Chronic and Autoimmune Diseases, Blood Disorders, Growth Hormone Deficiency, Infectious Diseases, Others
2) By Distribution Channels: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy.
View Complete Report:
Filgrastim Biosimilars Global Market Report 2020 is the most comprehensive report available on this market and will help gain a truly global perspective as it covers 60 geographies. The chapter on the impact of COVID-19 gives valuable insights on supply chain disruptions, logistical challenges, and other economic implications of the virus on the market. The chapter also covers markets which have been positively affected by the pandemic.
The global filgrastim biosimilars market is expected to decline from $511.15 million in 2019 to $445.04 million in 2020 at a compound annual growth rate (CAGR) of -12.93%. The decline is mainly due to the COVID-19 outbreak that has led to restrictive containment measures involving social distancing, remote working, and the closure of industries and other commercial activities resulting in operational challenges. The entire supply chain has been disrupted, impacting the market negatively. The market is then expected to recover and reach $751.96 billion in 2023 at a CAGR of 19.11%.
Companies in the filgrastim biosimilar market are increasing their product innovation through strategic collaborations. To sustain in the increasingly competitive market, companies are developing innovative products as well as sharing skills and expertise with other companies. While companies have long collaborated with each other and with academic and research institutions in this market by way of partnerships, in- or out-licensing deals, this trend has been increasing over recent years.
Few Points From The Table Of Contents
1. Executive Summary
2. Filgrastim Biosimilars Market Characteristics
3. Filgrastim Biosimilars Market Size And Growth
4. Filgrastim Biosimilars Market Segmentation
5. Filgrastim Biosimilars Market Regional And Country Analysis
25. Filgrastim Biosimilars Market Competitive Landscape And Company Profiles
26. Key Mergers And Acquisitions In The Filgrastim Biosimilars Market
27. Filgrastim Biosimilars Market Trends And Strategies
28. Filgrastim Biosimilars Market Future Outlook and Potential Analysis
Request For A Sample Report At:
Few Points From List Of Table
Table 1: Global Historic Market Growth, 2015-2019, $ Billion
Table 2: Global Forecast Market Growth, 2015-2019, 2023F, 2025F, 2030F, $ Billion
Table 3: Global Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
Table 45: Cadila Pharmaceuticals Financial Performance
Table 46: Dr. Reddy`s Laboratories Financial Performance
Table 47: Intas Biopharmaceuticals Financial Performance
Table 48: Sandoz Financial Performance
Table 49: Amgen Inc. Financial Performance
About The Business Research Company:
The Business Research Company is a Business Intelligence Company which excels in company, market and consumer research. It has offices in the UK, the US and India and a network of trained researchers in 15 countries globally.
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 8897263534
Americas: +1 315 623 0293
Email: [email protected]
Follow us on Blog: http://blog.tbrc.info/
Follow us on LinkedIn: https://in.linkedin.com/company/the-business-research-company